ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 1887 • ACR Convergence 2022

    Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study

    Shivani Rangaswamy1, Lisa Christopher-Stine2, Jemima Albayda2, Eleni Tiniakou2, Christopher Mecoli3, Brittany Adler2, Ellen Eline2, William Kelly2 and Julie Paik2, 1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box…
  • Abstract Number: 0157 • ACR Convergence 2022

    Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale

    Rohit Aggarwal1, Brendan Johnson2, Jolie Feldman3, Austin Gromatzky4 and Paul N Mudd Jr.2, 1Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Priovant Therapeutics, Durham, NC, 3Priovant Therapeutics, New York, NY, 4Priovant Therapeutics, Washington, DC

    Background/Purpose: Brepocitinib is a novel, orally available, TYK2/JAK1 inhibitor in Phase 3 development for the treatment of dermatomyositis (DM), a chronic immune-mediated disease of the…
  • Abstract Number: 0652 • ACR Convergence 2022

    Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway

    Shohei Nakamura, Yuko okamoto, Yasuhiro Katsumata and Masayoshi Harigai, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

    Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced…
  • Abstract Number: 1696 • ACR Convergence 2022

    Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus

    Grace Hile, Feiyang Ma, Amanda Victory, Bin Xu, Mehrnaz Gharaee-Kermani, Elisabeth Pedersen, Rachael Wasikowski, Celine Berthier, Vladimir Ognenovski, Allison Billi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM…
  • Abstract Number: 2239 • ACR Convergence 2022

    Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial

    Rohit Aggarwal1, Christina Charles-Schoeman2, joachim Schessl3, Victoria Werth4, Zsuzsanna Bata-Csorgo5, Mazen Dimachkie6, Zoltan Griger7, Sergey Moiseev8, Chester Oddis9, Elena Schiopu10, Jiří Vencovský11, Irene Beckmann12, Elisabeth Clodi13, Todd Levine14 and and the ProDERM investigators15, 1Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, 3Friedrich-Baur-Institut/Medical University Munich, Mainkofen, Germany, 4Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 5University of Szeged, Faculty of Medicine, Szeged, Hungary, 6University of Kansas Medical Center, Kansas City, KS, 7University of Debrecen, Debrecen, Hungary, 8First Moscow State Medical University, Moscow, Russia, 9University of Pittsburgh, Pittsburgh, PA, 10Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 11Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 12Octapharma PharmazeutikaProduktionsGesmbH, Vienna, Austria, 13Octapharma Pharmazeutika ProduktionsgesmbH, Vienna, Austria, 14Phoenix Neurological Associates, Ltd., Phoenix, AZ, 15Institutions in Europe and North America, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…
  • Abstract Number: 0159 • ACR Convergence 2022

    B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab

    Tam Quach1, Anne Davidson2 and Galina Marder3, 1Feinstein Institute for Medical Research, Manhasset, NY, 2Feinstein Institutes for Medical Research, Manhasset, NY, 3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

    Background/Purpose: Recent observations suggest the importance of the BAFF pathway in the pathogenesis of Idiopathic Inflammatory Myositis (IIM). Elevated serum levels of circulating BAFF in…
  • Abstract Number: 0717 • ACR Convergence 2022

    Treatment Utilization in Dermatomyositis: An Analysis of Electronic Medical Records in the United States

    Adrian Kielhorn1, Zheng Wang1, Kristin Moy1, Lisa Christopher-Stine2, Ingrid Lundberg3, Hector Chinoy4, Kaniah Gunter5 and Rohit Aggarwal6, 1Alexion, AstraZeneca Rare Disease, Boston, MA, 2Johns Hopkins University, Baltimore, MD, 3Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 4The University of Manchester, Sale, United Kingdom, 5Patient Author, Norfolk, VA, 6Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Dermatomyositis (DM) is a rare, chronic inflammatory disease characterized by skin manifestations and/or progressive muscle weakness and other systemic manifestations. Patients with DM were…
  • Abstract Number: 1838 • ACR Convergence 2022

    Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States

    Arielle Bensimon1, Kristina Chen2, Ahmed Noman1, Erica Yim1, Jason Xenakis3 and Rohit Aggarwal4, 1Analysis Group, Inc., Boston, MA, 2Pfizer Inc., Cambridge, MA, 3Pfizer Inc., New York, NY, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease characterized by muscle weakness, skin rashes, and elevated risk of associated conditions such as interstitial…
  • Abstract Number: 2240 • ACR Convergence 2022

    Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice

    Yuki Ichimura1, Risa Konishi1, Toshifumi Nomura2, Manabu Fujimoto3 and Naoko Okiyama1, 1Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, 2University of Tsukuba, Tsukuba, Ibaraki, Japan, 3Osaka University, Suita, Japan

    Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody-associated DM sometimes…
  • Abstract Number: 0161 • ACR Convergence 2022

    Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells

    DeAnna Diaz1, Thomas Vazquez2, Nilesh Kodali3, Madison Grinnell4, Emily Keyes4, Josh Dan4, Grant Sprow5, Muhammad Bashir6, Meena Sharma7 and Victoria Werth8, 1Philadelphia College of Medicine, Philadelphia, PA, 2FIU Wertheim College of Medicine, Virginia Beach, VA, 3New Jersey Medical School, Coppell, TX, 4Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 5Albert Einstein College of Medicine, Philadelphia, PA, 6University of Pennsylvania, Philadelphia, PA, 7Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 8University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…
  • Abstract Number: 0824 • ACR Convergence 2022

    Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis

    Cindy Flower, Queen Elizabeth Hospital, Christ Church, Barbados

    Background/Purpose: To describe selected epidemiologic, demographic and outcome data in a cohort of Afro-Caribbean patients diagnosed clinically with dermatomyositis. To demonstrate clinical features of the…
  • Abstract Number: 1848 • ACR Convergence 2022

    Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope

    Josh Dan1, Grant Sprow2, Josef Concha3, Nilesh Kodali4, DeAnna Diaz5, Felix Chin6, Thomas Vazquez7 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Albert Einstein College of Medicine, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4New Jersey Medical School, Coppell, TX, 5Philadelphia College of Medicine, Philadelphia, PA, 6University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 7FIU Wertheim College of Medicine, Virginia Beach, VA

    Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
  • Abstract Number: 2241 • ACR Convergence 2022

    Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network

    Fabricio Espinosa-Ortega1, Karin Lodin2, Marie Holmqvist1, Maryam Dastmalchi3, Angela Ceribelli4, Jiri Venkovsky5, Hector Chinoy6, Louise Diederichsen7, Samuel Shinjo8, Ingrid Lundberg9 and Helene Alexanderson1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska University hospital, Huddinge, Sweden, 3Karolinska University Hospital, Stockholm, Sweden, 4Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, 5Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic, Prague, Czech Republic, 6The University of Manchester, Sale, United Kingdom, 7Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, 8Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, 9Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) may harbor autoantibodies that are associated with well-defined clinical phenotypes. The association of these autoantibodies with level of…
  • Abstract Number: 0163 • ACR Convergence 2022

    Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic

    Christopher Costin1, Gabrielle Morgan2, Amer Khojah3 and Lauren Pachman4, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Umm Al-Qura University, Makkah, Saudi Arabia, 4Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

    Background/Purpose: Prior research has shown that viruses may trigger JDM, although the degree to which COVID-19 may serve as a trigger for JDM remains unknown.…
  • Abstract Number: 1066 • ACR Convergence 2022

    Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center

    Elvis Hysa, Carmen Pizzorni, Silvia Sammori, Emanuele Gotelli, Andrea Pogna, andrea cere, Carlotta Schenone, Veronica Gerli, sabrina Paolino, Alberto Sulli and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy

    Background/Purpose: Nailfold videocapillaroscopy (NVC) allows the safe and fast detection of different microvascular patterns in patients affected by autoimmune connective tissue diseases (CTDs). The prevalence of…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology